Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial). Am J Cardiol 2005 Feb 15;95(4):529-32
Date
02/08/2005Pubmed ID
15695147DOI
10.1016/j.amjcard.2004.10.026Scopus ID
2-s2.0-13844296683 (requires institutional sign-in at Scopus site) 29 CitationsAbstract
The comparison of treatment effect and co-morbidity between the genders in the Valsartan Heart Failure Trial showed equal benefit of treatment in men and women. Co-morbidities, such as diabetes and coronary artery disease, increased nonfatal cardiac morbidity more in women than in men.
Author List
Majahalme SK, Baruch L, Aknay N, Goedel-Meinen L, Hofmann M, Hester A, Prescott MF, Feliciano N, Val-HeFT Study InvestigatorsAuthor
Silja Majahalme MD, PhD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Angiotensin II Type 1 Receptor BlockersAntihypertensive Agents
Comorbidity
Coronary Artery Disease
Diabetes Mellitus
Double-Blind Method
Female
Heart Failure
Hospitalization
Humans
Male
Middle Aged
Severity of Illness Index
Sex Distribution
Tetrazoles
United States
Valine
Valsartan